间充质干细胞治疗产品开发现状与趋势

Development Status and Trend Analysis of Mesenchymal Stem Cells Therapeutic Products

目的:从产品开发角度分析间充质干细胞治疗产品的发展现状和未来趋势。方法:检索科睿唯安(Clarivate Analytics)的Cortellis数据库的数据,利用定量分析法和对比分析法对检索结果进行分析。结果:目前已有5种间充质干细胞治疗产品上市,9种间充质干细胞治疗产品处于注册及临床Ⅲ期,未来市场上的间充质干细胞治疗产品将呈现快速增长趋势。Mesoblast、FCB等公司在间充质干细胞治疗产品的拥有量上具有优势。间充质干细胞产业内部的商业交易也越来越多,目前共发生包括药物开发及商业化许可、专利资产出售以及早期药物研发合作等12起交易,其中药物开发及商业化许可是最主要的交易模式。尽管中国的间充质干细胞治疗产品研究尚处于起步阶段,但中国的西比曼生物、北科生物等公司已有多款产品处于临床阶段,中国本土的间充质干细胞治疗产品前景可期。结论:虽然间充质干细胞治疗产品市场尚处于起步阶段,但其技术发展快,市场需求大,相关企业产品研发与商品化积极性高,上升潜力巨大。

Objective： To analyze the development status and trend of Mesenchymal stem cells（ MSCs）therapeutic products in the sense of product manufacturing. Methods： Based on the Cortellis database of Clarivate Analytics,analyzed the searching results utilizing quantitative analysis and comparative analysis methods.Results： Currently,5 MSCs therapeutic products have been launched into markets, and another 9 MSCs therapeutic products are at registration phase or Phase III clinical trial. In addition,companies such as Mesoblast and FCB have an advantages over MSCs therapeutic products in the market. And business deals related to MSCs products are increasing in recent years,including 12 deals so far,ranging from drug development,commercial license,and patent assets sales to drug RD cooperation in early phase. Several MSCs therapeutic products are at clinical stage, and a bright prospect can be expected for Chinese MSCs therapeutic product markets.Conclusion： Although MSCs therapeutic product market still at its preliminary stage,the market potential is considerably huge since the fast-developing technologies,enormous market demand as well as the high motivation of related companies in MSCs RD and commercialization.